Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight/obesity patients with type 2 diabetes mellitus
Chenggang Dai, MDab,*, Weifeng Zhu, MDa

Abstract
Asprosin is a newly identified adipokine with glucose-raising and appetite-enhancing effects which acts differently from the known hepatic glucose utilization pathway. This study investigated changes in serum asprosin levels in normal weight or overweight/obese liraglutide-treated patients with type 2 diabetes (T2DM). This study is a non-randomized, prospective observational study. The metabolic parameters and asprosin levels were compared between 90 people with T2DM and 66 people who had normal glucose tolerance (NGT). During the treatment phase, only T2DM patients were given liraglutide at doses of 0.6 mg/d for the first 2 weeks, 1.2 mg/d for the subsequent 4 weeks, and 1.8 mg/d for the following 16 weeks. T2DM patients were separated into a normal weight group and an overweight/obesity group to compare changes in asprosin and parameters pre- and post-treatment. The T2DM group had significantly higher fasting asprosin and 2h-postprandial asprosin levels than the NGT group (all \( P < .001 \)). Fasting asprosin and postprandial asprosin positively correlated with BMI, 2hPG, HbA1c, TG, and HOMA-IR, and negatively correlated with HDL-C in both the T2DM and NGT groups. Asprosin levels decreased after liraglutide treatment in both normal and overweight/obesity T2DM groups (all \( P < .001 \)), with significantly reduced body weight and BMI in overweight/obese T2DM patients (all \( P < .001 \)). Fasting and postprandial serum asprosin concentrations are higher in T2DM patients compared to normal glucose controls. Fasting and postprandial asprosin positively correlated with BMI, 2hPG, HbA1c, TG, and HOMA-IR and negatively correlated with HDL-C in all participants. Liraglutide lowers asprosin levels in T2DM patients and can reduce weight and BMI in overweight or obese type 2 diabetics.

Abbreviations: 2hPG = 2h postprandial glucose, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BMI = body mass index, BUN = blood urea nitrogen, Cr = creatinine, DBP = diastolic blood pressure, eGFR = estimated glomerular filtration rate, FBG = fasting glucose, HbA1c = glycated hemoglobin, HDL-C = HDL cholesterol, HOMA-IR = Homeostatic Model Assessment of Insulin Resistance, LDL-C = LDL cholesterol, NGT = normal glucose tolerance, SBP = systolic blood pressure, T2DM = type 2 diabetes mellitus, TC = total cholesterol, TG = triglycerides, WC = waist circumference.

Keywords: asprosin, liraglutide, type 2 diabetes

1. Introduction
The prevalence of type 2 diabetes (T2DM) is rising globally resulting in serious complications that cause severe psychological and physical distress and place a considerable burden on healthcare systems. Most people with T2DM are overweight or obese, which can lead to insulin resistance (IR), beta-cell dysfunction, and chronic systemic inflammation, making blood glucose control more difficult. Therefore, when choosing T2DM medication, both blood glucose and body weight need to be taken into account.

Asprosin is an adipokine identified 6 years ago. It is a cleaved fragment of the C-terminus of profibrillin, which is secreted by white adipocytes and has gluconeogenic and appetite-enhancing effects that increase with fasting and decrease with feeding. Asprosin levels are significantly elevated in insulin-resistant states. Asprosin has a glycemic pathway that differs from the currently known classical hepatic glucose utilization pathway, thus providing new ideas and approaches for T2DM treatment by intervening in the asprosin glucagon pathway.

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are ideal for patients with overweight T2DM because they control blood glucose and promote weight loss. Liraglutide is a representative medication effectively used to treat overweight T2DM patients and has a low risk of hypoglycemia. Our experiment compared serum asprosin levels between NGT and T2DM people and investigated the correlation between asprosin and some important parameters. Then, we observed the effect of liraglutide on asprosin in normal weight patients with type 2 diabetes mellitus.
or overweight/obesity patients with T2DM to identify new targets for T2DM treatment.

This study investigated the effect of GLP-1RA liraglutide on important markers such as asprosin, body weight, blood glucose, and lipids in normal weight or overweight/obese T2DM patients to identify new targets for T2DM treatment.

2. Methods

2.1. Study design

Subjects: This study is a non-randomized, prospective observational study. From February 2021 to January 2022, 90 newly diagnosed T2DM patients according to the 2021 ADA guidelines\(^{10}\) were recruited from the Guangzhou Development District Hospital and the Affiliated TCM Hospital of Guangzhou University of Chinese Medicine (T2DM group). The T2DM group had a mean age of 54.91 ± 8.24 years, with 48 men and 42 women and were divided into two groups according to their BMI, normal weight (T2DM-N) and overweight or obese (T2DM-O). Overweight and obesity were defined using criteria of the Working Group on Obesity in China, overweight: BMI ≥ 24 kg/m\(^2\) and < 28 kg/m\(^2\), obesity: BMI ≥ 28 kg/m\(^2\).\(^{11}\)

The control group consisted of 66 age-matched individuals with normal glucose tolerance (NGT group), with a mean age of 52.15 ± 7.97 years, 35 males and 31 females.

Exclusion criteria: age < 18 or > 70 years old; type 1 diabetes; various acute diabetic complications; acute and chronic infections, tumors, haematological disorders, rheumatic disorders, liver, kidney, heart, or brain disease; glomerular filtration rate < 45 ml/min; patients unable to tolerate adverse drug reactions and discontinue the drug; history of alcohol abuse, pregnancy, and lactation; psychiatric disorders and previous and family history; those who had used drugs for the treatment of diabetes during the past 3 months; and Refusal to cooperate.

The T2DM group was treated with 0.6 mg/d of liraglutide for the first 2 weeks, 1.2 mg/d for the subsequent 4 weeks, and 1.8 mg/d for the following 16 weeks. Various indicators of the two T2DM groups (T2DM-N and T2DM-O) were measured at baseline and after treatment (22 weeks). The NGT group was not treated with placebo or liraglutide, and various indicators were only measured at baseline. The parameters included weight, height, waist circumference, and blood pressure. Weight was measured in “kg”, height, and waist circumference were measured in “cm” to the nearest 0.1 cm, and BMI was calculated by weight (kg) ÷ height (m)^2. Blood pressure was measured twice and then averaged to determine the final blood pressure value in mm Hg.

2.2. Biochemical analysis

The biomarkers included fasting glucose, postprandial glucose, glycated hemoglobin (HbA1c), blood urea nitrogen (BUN), creatinine (Cr), estimated glomerular filtration rate (eGFR), alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglycerides (TG), LDL cholesterol, and HDL cholesterol were analyzed in the Department of Laboratory Medicine of the Guangzhou Development District Hospital and the Affiliated TCM Hospital of Guangzhou University of Chinese Medicine.

2.3. Asprosin assay

Blood samples (5 mL) were collected from the participants through a median cubital vein at baseline and after treatment (22 weeks) while they were fasting and two hours after breakfast into sterile vacuum tubes. The plasma and serum were separated by centrifugation for 15 minutes (3000 rpm) and 1.5 ML serum aliquots were stored at −80°C. The asprosin levels were quantified using a commercially available human asprosin ELISA kit (E15190h, EIAAB Science Inc., Wuhan, China) with an assay range of 1.56–100 ng/mL and analytical sensitivity of 0.938 ng/mL. The intra-assay and inter-assay coefficient of variation (CV) values were < 8% and < 10%.

2.4. Pancreatic islet function

Fasting insulin was assayed by chemiluminescence and measured in μU/mL. The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) was calculated as (fasting glucose (FPG, mmol/L) × fasting insulin (FINS, μU/ml))/22.5.

2.5. Statistical analysis

The statistical evaluations were conducted utilizing SPSS 23.0 (IBM). The Kolmogorov-Smirnov test was used to determine whether the distribution was normally distributed. The data was displayed as mean standard deviation (SD). The NGT and T2DM groups were compared by the student’s t test. Paired student t tests were used to compare the statistical variances between the pre- and post-treatment periods. To analyze proportional differences, the chi-square test was used. The correlation between baseline metabolic parameters and serum asprosin levels was evaluated using the Pearson correlation coefficient. \(P = .05\) were regarded as statistically significant in all two-tailed statistical tests.

2.6. Ethics statement

The study was approved by the Ethics Committee of the Guangzhou Development District Hospital and the Affiliated TCM Hospital of Guangzhou University of Chinese Medicine (Ethics No. KY2021-002) and conducted according to the principles embodied in the “Declaration of Helsinki” (2013). All participants clearly understood the process and purpose of this study. Consent forms were signed before the experiment.

3. Results

No patients stopped treatment or withdrew from the study. Short-term nausea and diarrhea occurred in two normal weight T2DM patients and three overweight/obese T2DM patients treated with liraglutide. The flow diagram of the study was shown in Figure 1.

3.1. Baseline clinical characteristics

Table 1 presents the baseline clinical characteristics of the study participants showing that the T2DM and NGT groups were similar in age, sex, BMI, SBP, DBP, BUN, Cr, eGFR, AST, ALT, TC, TG, HDL-C, and LDL-C (all \(P > .05\)). However, the T2DM patients had significantly higher FBG, 2h postprandial glucose (2hPG), HbA1c, HOMA-IR levels than the NGT subjects (all \(P < .05\)). The serum fasting asprosin and postprandial asprosin levels were significantly higher in the T2DM group than in the NGT group \((P < .001)\) (Fig. 2).

3.2. Correlation of asprosin with parameters at the baseline (Table 2) (Fig. 3)

Correlation analysis of the T2DM group at baseline revealed that fasting asprosin levels positively correlated with BMI \((r = 0.247, P = .019)\), FBG \((r = 0.433, P < .001)\), 2hPG \((r = 0.290, P = .006)\), HbA1c \((r = 0.268, P = .011)\), TG \((r = 0.282, P = .007)\), HOMA-IR \((r = 0.267, P = .011)\) and was negatively correlated with HDL-C \((r = -0.295, P = .005)\). Postprandial asprosin concentration was positively correlated
Figure 1. The flow diagram of the study. NGT = normal glucose tolerance, T2DM = type 2 diabetes mellitus, T2DM-N = normal weight T2DM, T2DM-O = overweight or obese T2DM.

Table 1
Baseline clinical characteristics of the study participants.

| Characteristics | NGT (n = 66) | T2DM (n = 90) | t/\chi^2 | P     |
|-----------------|-------------|--------------|---------|-------|
| Age (yr)        | 52.15 ± 7.97| 54.91 ± 8.24 | -2.160  | .032  |
| Gender (men/women) | 35/31     | 48/42        | 0.001  | .970  |
| overweight/obesity (yes/no) | 36/30     | 55/35        | 0.675  | .411  |
| Body weight (kg) | 64.19 ± 10.54| 70.46 ± 10.34| -3.712 | <.001 |
| BMI (kg/m²)   | 24.04 ± 2.11| 25.56 ± 3.44 | -3.163 | .002  |
| WC (cm)        | 87.64 ± 6.81| 95.22 ± 11.22| -4.864 | <.001 |
| SBP (mm Hg)   | 128.14 ± 10.16| 130.88 ± 12.13| -1.490 | .138  |
| DBP (mm Hg)   | 78.37 ± 5.05| 75.53 ± 5.55 | 1.658  | .099  |
| BUN (mmol/L)  | 4.45 ± 1.05| 4.78 ± 1.22 | -1.811 | .072  |
| Cr (μmol/L)   | 77.79 ± 17.24| 74.44 ± 21.85| 1.032  | .304  |
| eGFR (mL/min/1.73 m²) | 118.21 ± 14.92| 114.38 ± 13.24| 1.691  | .093  |
| AST (U/L)      | 30.52 ± 6.64| 32.39 ± 6.85 | -1.711 | .089  |
| ALT (U/L)      | 29.32 ± 5.76| 31.66 ± 8.08 | -1.486 | .139  |
| FBS (mmol/L)  | 5.25 ± 0.55| 10.16 ± 3.26 | -12.118| <.001 |
| HbA1c (%)      | 5.36 ± 0.43| 7.61 ± 1.24 | -14.207| <.001 |
| TG (mmol/L)    | 4.14 ± 0.51| 4.31 ± 0.81 | -1.499 | .136  |
| HDL-C (mmol/L)| 1.89 ± 0.48| 1.97 ± 0.64 | -0.766 | .445  |
| LDL-C (mmol/L)| 1.23 ± 0.31| 1.14 ± 0.29 | 1.918  | .057  |
| 2hPG (mmol/L) | 2.36 ± 0.48| 2.50 ± 0.73 | -1.382 | .169  |
| HOMA-IR        | 6.91 ± 1.35| 16.05 ± 4.53| -15.870| <.001 |
| Fasting asprosin (ng/mL) | 1.59 ± 0.41| 3.40 ± 0.65 | -19.758| <.001 |
| Postprandial asprosin (ng/mL) | 5.87 ± 0.71| 7.30 ± 1.08 | -9.882 | <.001 |

Data are presented as mean ± standard deviation or as otherwise.
2hPG = 2h postprandial glucose, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BMI = body mass index, BUN = blood urea nitrogen, Cr = creatinine, DBP = diastolic blood pressure, eGFR = estimated glomerular filtration rate, FBS = fasting glucose, HbA1c = glycated hemoglobin, HDL-C = HDL cholesterol, HOMA-IR = Homeostatic Model Assessment of Insulin Resistance, LDL-C = LDL cholesterol, NGT = normal glucose tolerance, SBP = systolic blood pressure, T2DM = type 2 diabetes mellitus, TC = total cholesterol, TG = triglycerides, WC = waist circumference.
with BMI ($r = 0.269$, $P = .010$), FBG ($r = 0.429$, $P < .001$), 2hPG ($r = 0.271$, $P = .010$), HbA1c ($r = 0.299$, $P = .004$), TG ($r = 0.256$, $P = .015$), HOMA-IR ($r = 0.250$, $P = .017$) and was negatively correlated with HDL-C ($r = −0.292$, $P = .005$).

Fasting asprosin in the NGT group at baseline positively correlated with BMI ($r = 0.252$, $P = .041$), FBG ($r = 0.394$, $P = .001$), 2hPG ($r = 0.299$, $P = .015$), HbA1c ($r = 0.331$, $P = .007$), TG ($r = 0.385$, $P = .001$), HOMA-IR ($r = 0.303$, $P = .014$) and negatively correlated with HDL-C ($r = −0.279$, $P = .023$). Postprandial asprosin positively correlated with BMI ($r = 0.304$, $P = .013$), FBG ($r = 0.441$, $P < .001$), 2hPG ($r = 0.354$, $P = .004$), HbA1c ($r = 0.346$, $P = .004$), TG ($r = 0.442$, $P < .001$), HOMA-IR ($r = 0.292$, $P = .017$) and negatively correlated with HDL-C ($r = −0.337$, $P = .006$).

### Table 2

| Characteristics     | NGT fasting asprosin | NGT postprandial asprosin | T2DM fasting asprosin | T2DM postprandial asprosin |
|---------------------|-----------------------|----------------------------|------------------------|-----------------------------|
| Age                 | $r = 0.160$            | $P = .198$                 | $r = 0.183$            | $P = .141$                 |
| Body weight         | $r = 0.134$            | $P = .282$                 | $r = 0.145$            | $P = .244$                 |
| BMI                 | $r = 0.252$            | $P = .041$                 | $r = 0.304$            | $P = .013$                 |
| WC                  | $r = 0.162$            | $P = .194$                 | $r = 0.105$            | $P = .400$                 |
| SBP                 | $r = 0.114$            | $P = .361$                 | $r = 0.176$            | $P = .156$                 |
| DBP                 | $r = 0.211$            | $P = .090$                 | $r = 0.225$            | $P = .069$                 |
| BUN                 | $r = 0.206$            | $P = .096$                 | $r = 0.135$            | $P = .280$                 |
| Cr                  | $r = 0.131$            | $P = .296$                 | $r = 0.100$            | $P = .423$                 |
| eGFR                | $r = -0.146$           | $P = .242$                 | $r = -0.018$           | $P = .888$                 |
| AST                 | $r = 0.186$            | $P = .134$                 | $r = 0.224$            | $P = .071$                 |
| ALT                 | $r = 0.130$            | $P = .297$                 | $r = 0.153$            | $P = .221$                 |
| FBG                 | $r = 0.394$            | $P = .001$                 | $r = 0.441$            | $< .001$                  |
| 2hPG                | $r = 0.299$            | $P = .015$                 | $r = 0.354$            | $P = .004$                 |
| HbA1c               | $r = 0.331$            | $P = .007$                 | $r = 0.346$            | $P = .004$                 |
| TC                  | $r = 0.237$            | $P = .055$                 | $r = 0.154$            | $P = .218$                 |
| TG                  | $r = 0.385$            | $P = .001$                 | $r = 0.442$            | $< .001$                  |
| HDL-C               | $r = -0.270$           | $P = .023$                 | $r = -0.337$           | $< .001$                  |
| LDL-C               | $r = 0.168$            | $P = .176$                 | $r = 0.152$            | $P = .223$                 |
| HOMA-IR             | $r = 0.303$            | $P = .014$                 | $r = 0.292$            | $P = .017$                 |

2hPG = 2h postprandial glucose, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BMI = body mass index, BUN = blood urea nitrogen, Cr = creatinine, DBP = diastolic blood pressure, eGFR = estimated glomerular filtration rate, FBG = fasting glucose, HbA1c = glycated hemoglobin, HDL-C = HDL cholesterol, HOMA-IR = Homeostatic Model Assessment of Insulin Resistance, LDL-C = LDL cholesterol, NGT = normal glucose tolerance, SBP = systolic blood pressure, T2DM = type 2 diabetes mellitus, TC = total cholesterol, TG = triglycerides, WC = waist circumference.

### 4. Discussion

This study found that the T2DM group had more abnormal metabolic markers than NGT controls. Also, serum asprosin concentrations were higher in T2DM than in those with NGT, both in the fasting and postprandial states, in line with previous research. Some studies have shown that fasting and postprandial asprosin levels are higher in T2DM individuals than in those with NGT and that fasting asprosin levels are strongly associated with T2DM. Another study compared 84 adults with T2DM to 86 people with NGT showing that the adults with T2DM had considerably higher serum asprosin concentrations than controls. Therefore, asprosin may be a risk factor for T2DM pathogenesis.

The present study also revealed a positive correlation between fasting asprosin or postprandial asprosin and BMI, 2hPG, HbA1c, TG, HOMA-IR, and a negative correlation with HDL-C, broadly in line with previous studies. Unlike previous reports, no correlation between asprosin and waist circumference was found in this study. Considering that height and weight vary among individuals, waist circumference values alone may not be a true reflection of the degree of obesity, which may account for the lack of correlation between asprosin and waist circumference. Another potential reason is ethnic variability, as Asians have a high visceral fat content but do not have a prominent waist circumference.

### Figure 2

The serum fasting asprosin and postprandial asprosin levels between the T2DM group and the NGT group in baseline. NGT = normal glucose tolerance, T2DM = type 2 diabetes mellitus.
WC, fasting glucose, postprandial glucose, HbA1c, TC, TG, LDL-C, HOMA-IR, and asprosin concentrations decreased and HDL-C increased after liraglutide treatment in both normal weight or overweight/obese patients with T2DM compared to baseline. In particular, weight and BMI decreased in obese patients with T2DM. Consistent with previous studies, liraglutide reduced WC, glucose, lipid, and asprosin levels in patients with T2DM.

GLP-1 is influenced by feeding activity. It is released from the intestinal tissues into the blood immediately after a meal and promotes insulin secretion, increasing glucose uptake and glycosyn synthesis and reducing glucagon production. It delays gastric emptying, making people feel fuller and less hungry, so effectively reduces body mass in obese diabetics as well as improves blood glucose levels in diabetics.\(^\text{[17]}\)

GLP-1RA, particularly liraglutide, facilitates weight loss by suppressing appetite, reducing food intake, significantly increasing the level of satiety signals in the hypothalamic arcuate nucleus, and inhibiting the increase in hunger signals in the arcuate nucleus, thereby increasing satiety and reducing caloric intake; increasing energy expenditure, promoting the conversion of visceral white fat to brown fat, and promoting brown fat thermogenesis; and affecting gastrointestinal motility, prolonging gastric emptying time, and reducing gastric acid secretion stimulated by pentagastrin. It is important to note that it has little effect on weight loss in people with low-fat content.\(^\text{[14]}\)

In this study, glucose and HbA1c control in both T2DM groups (T2DM-N and T2DM-O) were better after treatment. Insulin resistance was also alleviated. Weight and BMI in obese type 2 diabetic patients decreased dramatically with treatment. Clinical trials have shown that liraglutide helps with weight loss. A single-center study in Belgium showed that obese patients treated with liraglutide for 4 months had considerable weight loss regardless of the maximum tolerated maintenance dose. Weight loss was significant even when the maximum daily dose was not reached.\(^\text{[19]}\)

However, despite a decrease in body weight and BMI in the normal weight T2DM group after treatment, the difference was not statistically significant. Liraglutide may have a limited effect on weight loss in normal weight individuals. More trials are needed to confirm this.

### Table 3

Comparison of biochemical parameters before and after treatment with liraglutide in the type 2 diabetes group.

| Characteristics         | T2DM-N (n = 35) | T2DM-O (n = 55) | t | P    |
|-------------------------|----------------|----------------|---|------|
| Body weight (kg)        | 62.08 ± 7.43   | 59.84 ± 5.89   | 1.374 | .179 |
| BMI (kg/m²)             | 21.95 ± 1.56   | 21.39 ± 1.67   | .84 | .407 |
| WC (cm)                 | 84.04 ± 4.13   | 81.95 ± 4.55   | 2.194 | .035 |
| SBP (mm Hg)             | 78.69 ± 5.02   | 77.43 ± 5.83   | .816 | .639 |
| DBP (mm Hg)             | 4.49 ± 1.35    | 4.34 ± 1.45    | .199 | .843 |
| Cr (μmol/L)             | 75.57 ± 21.11  | 67.54 ± 15.90  | 1.775 | .083 |
| eGFR (mL/min/1.73 m²)   | 114.58 ± 10.32 | 117.67 ± 11.47 | 1.246 | .221 |
| AST (U/L)               | 32.01 ± 4.76   | 29.78 ± 6.48   | 1.527 | .127 |
| ALT (U/L)               | 29.24 ± 7.15   | 28.17 ± 6.75   | .719 | .478 |
| FBG (mmol/L)            | 9.33 ± 2.73    | 8.65 ± 0.83    | 3.21 | <.001 |
| 2hPG (mmol/L)           | 15.48 ± 3.84   | 15.00 ± 2.26   | 1.45 | .151 |
| HbA1c (%)               | 4.07 ± 0.78    | 3.53 ± 0.60    | 3.95 | <.001 |
| TC (mmol/L)             | 1.81 ± 0.38    | 1.37 ± 0.37    | 4.68 | <.001 |
| T2DM-N (n = 35)         | 21.95 ± 1.56   | 21.39 ± 1.67   | .84 | .407 |
| T2DM-O (n = 55)         | 21.39 ± 1.67   | 21.39 ± 1.67   | .164 | .871 |
| BW (kg)                 | 1.374 | .179 |
| BMI (kg/m²)             | 2.194 | .035 |
| WC (cm)                 | 1.775 | .083 |
| SBP (mm Hg)             | 1.246 | .221 |
| DBP (mm Hg)             | 1.527 | .127 |
| Cr (μmol/L)             | 3.21 | .151 |
| eGFR (mL/min/1.73 m²)   | 4.68 | <.001 |
| AST (U/L)               | 3.95 | <.001 |
| ALT (U/L)               | 1.45 | .151 |
| FBG (mmol/L)            | 3.71 | .053 |
| 2hPG (mmol/L)           | 5.17 | .015 |
| HbA1c (%)               | 4.17 | .078 |
| TC (mmol/L)             | 4.37 | <.001 |
| T2DM-N (n = 35)         | 59.84 ± 5.89   | 59.84 ± 5.89   | .179 | .179 |
| T2DM-O (n = 55)         | 59.84 ± 5.89   | 59.84 ± 5.89   | .179 | .179 |
| Body weight (kg)        | 59.84 ± 5.89   | 59.84 ± 5.89   | .179 | .179 |
| BMI (kg/m²)             | 59.84 ± 5.89   | 59.84 ± 5.89   | .179 | .179 |
| WC (cm)                 | 59.84 ± 5.89   | 59.84 ± 5.89   | .179 | .179 |
| SBP (mm Hg)             | 59.84 ± 5.89   | 59.84 ± 5.89   | .179 | .179 |
| DBP (mm Hg)             | 59.84 ± 5.89   | 59.84 ± 5.89   | .179 | .179 |
| Cr (μmol/L)             | 59.84 ± 5.89   | 59.84 ± 5.89   | .179 | .179 |
| eGFR (mL/min/1.73 m²)   | 59.84 ± 5.89   | 59.84 ± 5.89   | .179 | .179 |
| AST (U/L)               | 59.84 ± 5.89   | 59.84 ± 5.89   | .179 | .179 |
| ALT (U/L)               | 59.84 ± 5.89   | 59.84 ± 5.89   | .179 | .179 |
| FBG (mmol/L)            | 59.84 ± 5.89   | 59.84 ± 5.89   | .179 | .179 |
| 2hPG (mmol/L)           | 59.84 ± 5.89   | 59.84 ± 5.89   | .179 | .179 |
| HbA1c (%)               | 59.84 ± 5.89   | 59.84 ± 5.89   | .179 | .179 |
| TC (mmol/L)             | 59.84 ± 5.89   | 59.84 ± 5.89   | .179 | .179 |
| T2DM-N (n = 35)         | 59.84 ± 5.89   | 59.84 ± 5.89   | .179 | .179 |
| T2DM-O (n = 55)         | 59.84 ± 5.89   | 59.84 ± 5.89   | .179 | .179 |

Data are presented as mean ± standard deviation.

2hPG = 2h postprandial glucose, ALT = alanine aminotransferase, AST = aspartate aminotransferase, BMI = body mass index, BUN = blood urea nitrogen, Cr = creatinine, DBP = diastolic blood pressure, eGFR = estimated glomerular filtration rate, FBG = fasting glucose, HbA1c = glycated hemoglobin, HDL-C = HDL cholesterol, HOMA-IR = Homeostatic Model Assessment of Insulin Resistance, LDL-C = LDL cholesterol, SBP = systolic blood pressure, T2DM-N = type 2 diabetes mellitus with normal weight, T2DM-O = type 2 diabetes mellitus with overweight/obese, TC = total cholesterol, TG = triglycerides, WC = waist circumference.
Asprosin was decreased in T2DM patients after liraglutide treatment, which is consistent with previous studies. The reason may be the hypolipidemic effect of liraglutide. Because asprosin is synthesized from adipose tissue, asprosin may decrease with the reduction of adipose tissue. This needs to be further verified. Liraglutide has a direct stimulatory effect on Pro-opiomelanocortin (POMC) neurons and inhibits Agouti-related peptide (AgRP) neurons, lowering appetite and increasing satiety.\textsuperscript{[20]} In contrast, asprosin crosses the blood-brain barrier and activates pro-appetitive AgRP neurons, and inhibits anorexic POMC neurons via the G protein-cAMP-PKA pathway.\textsuperscript{[21]} Liraglutide may antagonize the neuronal activity of asprosin, thereby suppressing appetite and reducing body weight.

Some studies have demonstrated higher asprosin concentrations in people with abnormal blood glucose. Asprosin deficiency may lead to loss of appetite and extreme leanness.\textsuperscript{[22]} Diminished asprosin activity or asprosin depletion could be an innovative therapeutic modality for the treatment of T2DM and obesity, thus a potential target for diabetes treatment.\textsuperscript{[23]}

Figure 4. Fasting asprosin levels between after treatment and before treatment. T2DM-N = normal weight T2DM, T2DM-O = overweight or obese T2DM.

Figure 5. Postprandial asprosin levels between after treatment and before treatment. T2DM-N = normal weight T2DM, T2DM-O = overweight or obese T2DM.

Liraglutide can reduce SBP compared to placebo, however, when the intervention lasted more than 1 year, the difference was no longer significant.\textsuperscript{[24]} Furthermore, the effect of liraglutide on blood pressure was dose-dependent. A study in patients with coronary artery disease with abnormal blood glucose showed that liraglutide had no significant effect on blood pressure.\textsuperscript{[25]} Another study evaluated the effectiveness of dulaglutide versus liraglutide, with only dulaglutide significantly lowering systolic blood pressure after 12 months.\textsuperscript{[26]} In our study, liraglutide did not affect SBP and the reason for this discrepancy in studies needs to be confirmed.

Few studies have investigated the effects of liraglutide on asprosin. In this study, T2DM patients were separated into two groups based on their weight, normal weight or overweight/obese to evaluate the effects of liraglutide on waist circumference, body mass, BMI, and asprosin. Additionally, only a few studies have observed postprandial asprosin before and after drug treatment. The present study specifically examined the changes in postprandial asprosin before and after treatment, as well as exploring the correlation between postprandial asprosin at baseline and indicators such as body weight, blood glucose, and blood lipids.

4.1. Limitations
This study has several limitations. The sample size was relatively small and further larger studies should be performed. In addition, lifestyle interventions are a cornerstone of first-line T2DM treatment, so the impact of lifestyle changes on the effectiveness of liraglutide treatment cannot be excluded. Studies have shown that exercise can reduce asprosin levels.\textsuperscript{[27,28]} Factors such as exercise and dietary patterns were not included in our study, so we cannot exclude the effect of lifestyle changes on asprosin. We did not systematically evaluate lifestyle changes, so we cannot rule out the impact of lifestyle changes on asprosin. Physical activities and dietary modifications could be included in the follow-up studies. Nevertheless, as a preliminary study, the findings are relevant to clinical practice.

5. Conclusion
In conclusion, fasting and postprandial asprosin concentrations in T2DM are higher than in those with NGT and fasting asprosin and postprandial asprosin positively correlated with BMI, 2hPG, HbA1c, TG, HOMA-IR, and negatively correlated with HDL-C. WC, FBG, postprandial glucose, HbA1c, TC, TG, LDL-C, HOMA-IR, and asprosin decreased and HDL increased in T2DM patients after liraglutide treatment, in particular, liraglutide caused a considerable decrease in body weight and BMI in overweight/obese T2DM patients. The precise mechanisms by which the GLP1-RA decreases the level of asprosin and how liraglutide may antagonize these mechanisms remain to be clarified. It can be assumed that liraglutide may antagonize asprosin activity thus inhibiting appetite and causing weight loss but further studies are needed to elucidate these complex signaling mechanisms.

Author contributions
Conceptualization: Chenggang Dai, Weifeng Zhu.
Data curation: Chenggang Dai.
Formal analysis: Chenggang Dai.
Investigation: Chenggang Dai.
Methodology: Chenggang Dai.
Resources: Chenggang Dai, Weifeng Zhu.
Software: Chenggang Dai.
Supervision: Weifeng Zhu.
Writing – original draft: Chenggang Dai.
Writing – review & editing: Weifeng Zhu.
References

[1] Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389:2239–51.

[2] Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55:31–55.

[3] Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nat Med. 2017;23:804–14.

[4] Tong Y, Xu S, Huang L, Chen C. Obesity and insulin resistance: pathophysiology and treatment. Drug Discov Today. 2022;27:822–30.

[5] Romere C, Duerrschmid C, Bournat J, et al. Asprosin, a fasting-induced glucogenic protein hormone. Cell. 2016;165:566–79.

[6] Duerrschmid C, He Y, Wang C, et al. Asprosin is a centrally acting orexigenic hormone. Nat Med. 2017;23:1444–53.

[7] Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314:687–99.

[8] Muller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72–130.

[9] Ostoft SH, Bagger JJ, Hansen T, et al. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. Diabetes Care. 2014;37:1797–805.

[10] American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S15–33.

[11] Chen C, Lu FC; Department of Disease Control Ministry of Health, PR China. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed Environ Sci. 2004;17(Suppl):1–36.

[12] Zhang L, Chen C, Zhou N, Fu Y, Cheng X. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride. Clin Chim Acta. 2019;489:183–8.

[13] Hong T, Li JY, Wang YD, et al. High Serum asprosin levels are associated with presence of metabolic syndrome. Int J Endocrinol. 2021;2021:6622129.

[14] Wang Y, Qu H, Xiong X, et al. Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion. Mediators Inflamm. 2018;2018:9471583.

[15] Lim U, Monroe KR, Buchthal S, et al. Propensity for intra-abdominal and hepatic adiposity varies among ethnic groups. Gastroenterology. 2019;156:966–975.e10.

[16] Holst JJ, Jepsen SL, Modvig I. GLP-1 – incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy. Curr Opin Pharmacol. 2022;63:102189.

[17] Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740–56.

[18] Trenson L, Trenson S, van Nes F, et al. Liraglutide for weight management in the real world: significant weight loss even if the maximal daily dose is not achieved. Obes Facts. 2022;15:83–9.

[19] He Z, Gao Y, Lieu L, et al. Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons - Implications for energy balance and glucose control. Mol Metab. 2019;28:120–34.

[20] Hoffmann JG, Xie W, Chopra AR. Energy regulation mechanism and therapeutic potential of asprosin. Diabetes. 2020;69:559–66.

[21] Naiemian S, Naeemipour M, Zarei M, et al. Serum concentration of asprosin in new-onset type 2 diabetes. Diabetol Metab Syndr. 2020;12:65.

[22] Bhadel P, Shrestha S, Sapkota B, Li JY, Tao H. Asprosin and type 2 diabetes mellitus: a novel potential therapeutic implication. J Biol Regul Homeost Agents. 2020;34:1.

[23] Zhao X, Huang K, Zheng M, Duan J. Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials. BMJ Endocr Disord. 2019;19:4.

[24] Kumarathurai P, Anholm C, Fabricius-Bjerre A, et al. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study. J Hypertens. 2017;35:1070–8.

[25] Chang KC, Shao SC, Kuo S, et al. Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis. Cardiovasc Diabetol. 2020;19:172.

[26] Ko JR, Seo DY, Kim TN, et al. Aerobic exercise training decreases hepatic asprosin in diabetic rats. J Clin Med. 2019;8:666.

[27] Akbulut T, Cinar V, Ugur K, Yarindm M, Karagöz ZK, Aydin S. Effect of regular exercise on the levels of subfatin and asprosin: a trial with different types of exercise. Eur Rev Med Pharmacol Sci. 2022;26:2683–91.